Lobe Sciences Provides Update on L-130 Clinical Program
Lobe Sciences Ltd. ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company's lead clinical program, L-130, a proprietary stabilized...
Philip Young Lobe Sciences Ltd Lobe Sciences Provides Lobe Sciences Clinical Program Sciences Provides Update
Source: lelezard.com